Schittenhelm L, Hilkens CM, Morrison VL.
β2 Integrins As Regulators of Dendritic Cell, Monocyte, and Macrophage Function.
Frontiers in Immunology 2017, 8, 1866.

Copyright:
© 2017 Schittenhelm, Hilkens and Morrison. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

DOI link to article:
https://doi.org/10.3389/fimmu.2017.01866

Date deposited:
23/01/2018

This work is licensed under a Creative Commons Attribution 4.0 International License

Newcastle University ePrints - eprint.ncl.ac.uk
β2 Integrins As Regulators of Dendritic Cell, Monocyte, and Macrophage Function

Leonie Schittenhelm1,2,3, Catharien M. Hilkens2,3 and Vicky L. Morrison1,3*

1 Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 2 Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 3 Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), Glasgow, United Kingdom

OPEN ACCESS

Edited by:
Andrew L. Mellor,
Newcastle University,
United Kingdom

Reviewed by:
Jeffrey Louis Curtis,
University of Michigan,
United States
Hans Acha-Orbea,
University of Lausanne,
Switzerland

*Correspondence:
Vicky L. Morrison
vicky.morrison@glasgow.ac.uk

INTRODUCTION

The integrin family of proteins is comprised of 24 heterodimeric transmembrane adhesion receptors. Each integrin is formed through the non-covalent association of 1 α-subunit and 1 β-subunit; currently, 16 α-subunits and 8 β-subunits have been identified. Their expression on virtually all human cells and their complex signaling mechanisms explain their wide variety of biological roles, including blood clotting, cell adhesion, and migration.

Due to their extensive importance in biological systems, elucidating integrin signaling and receptor function has been of great interest since their characterization as adhesion molecules over 30 years ago. Integrins are important signaling proteins that mediate interactions of the cell with extracellular matrix proteins and with other cells via cell-surface ligands. Integrins exist in a continuum between a folded inactive form with low affinity for their ligand and an extended high affinity conformation (1), although even bent integrins are able to bind ligand in rare instances (2). As immune cell adhesion and extravasation into lymph nodes and tissues forms part of initiating an effective immune response, β2 integrin conformation on the surface of leukocytes needs to be tightly regulated. β2 integrins on the surface of circulating leukocytes tend, therefore, to be largely inactive (2) until inside-out and outside-in signaling trigger integrin-mediated adhesion and extravasation into tissue (Figure 1).

Emerging evidence suggests that the β2 integrin family of adhesion molecules have an important role in suppressing immune activation and inflammation. β2 integrins are important adhesion and signaling molecules that are exclusively expressed on leukocytes. The four β2 integrins (CD11a, CD11b, CD11c, and CD11d paired with the β2 chain CD18) play important roles in regulating three key aspects of immune cell function: recruitment to sites of inflammation; cell–cell contact formation; and downstream effects on cellular signaling. Through these three processes, β2 integrins both contribute to and regulate immune responses. This review explores the pro- and anti-inflammatory effects of β2 integrins in monocytes, macrophages, and dendritic cells and how they influence the outcome of immune responses. We furthermore discuss how imbalances in β2 integrin function can have far-reaching effects on mounting appropriate immune responses, potentially influencing the development and progression of autoimmune and inflammatory diseases. Therapeutic targeting of β2 integrins, therefore, holds enormous potential in exploring treatment options for a variety of inflammatory conditions.

Keywords: β2 integrins, CD11/CD18, dendritic cells monocytes and macrophages, immune regulation, autoimmunity
Inside-out signaling modifies how cells interact with their environment by facilitating receptor affinity and avidity (4) to allow binding to extracellular ligands. Outside-in signaling, on the other hand, mediates intracellular events in response to their environment by eliciting downstream signaling cascades in response to receptor occupation. The complex details of integrin signaling are reviewed elsewhere (5, 6) and are beyond the scope of this review. Briefly, inside-out signaling is mediated by talin (7) and kindlin (8, 9) binding to the intracellular domain of the β2 subunit, a process initiated by chemokine receptor or Toll-like receptor (TLR) engagement (10, 11), which results in a conformational change in the integrin from a low-affinity to a high-affinity state. Outside-in signaling is then initiated by ligand binding to high-affinity integrin receptors (Figure 1). Downstream signaling events mediate the formation of focal complexes and adhesions through rearrangement of the actin cytoskeleton. The relative importance of affinity and avidity on integrin signaling and function is heavily debated (12, 13), but dynamic interaction between these processes and both inside-out and outside-in signaling seems likely (14).

β2 integrins are the focus of this review, as they are exclusively found on leukocytes and therefore of particular importance for the immune system. They mediate cell recruitment into lymphoid organs and inflamed tissues by facilitating firm leukocyte arrest on endothelial cells and extravasation after cell rolling (15); cellular interactions between leukocytes including immunological synapse formation (16); and intracellular signaling cascades that influence cytoskeletal rearrangement, activation, proliferation and impact on cellular responses to TLRs. Importantly, through these three processes, β2 integrins can have either pro-inflammatory or anti-inflammatory outcomes. The β2 integrin subunit (CD18) can pair with one of four α-subunits (αL—CD11a, αM—CD11b, αS—CD11c, and αD—CD11d), forming leukocyte function-associated antigen-1, Mac1/CR3 (macrophage-1 antigen, complement receptor 3), P150,95/CR4 (complement receptor 4), and CD18/CD11d, respectively (Figure 2). For consistency, this review will utilize only the CD nomenclature. Both function and cell-specific expression of β2 integrins vary according to the α-subunit involved.

The main ligands for the β2 integrin family members are outlined in Figure 2. Briefly, CD11a binds to intracellular adhesion molecule-1 (ICAM-1), -2, -3, and -5, which are expressed by a variety of cells including leukocytes and endothelial cells, thereby mediating leukocyte recruitment to lymph nodes and sites of inflammation as well as cell–cell adhesion. CD11b binds the complement proteins iC3b and C4b with high affinity, mediating phagocytosis of complement-coated particles but can also bind ICAM-1, fibrinogen, and more than 40 other ligands (17). The sequence of CD11c is very close to that of CD11b, and indeed CD11c binds several of the same ligands including iC3b, ICAM-1, and fibrinogen. Multi-ligand binding capacity of CD11d is proposed to largely overlap with CD11b and includes ECM-associated proteins fibronectin, fibrinogen, vitronectin, Cyr61, and plasminogen (18).

This review will provide an overview of β2 integrin expression on monocytes, macrophages and DCs, before exploring the paradoxical pro-inflammatory and regulatory roles of β2 integrins in immune regulation in three key aspects of immune function: recruitment and migration, cellular interactions, and downstream cell signaling (Figure 3). We will furthermore review how dysregulated integrin signaling could contribute to inflammatory and autoimmune conditions and introduce the therapeutic potential of targeting β2 integrins.

**Expression of β2 Integrin Subunits by Dendritic Cells (DCs), Monocytes, and Macrophages**

The expression of β2 integrin subunits varies in different leukocyte subsets and between mice and humans. In general terms, CD11a is expressed on all leukocytes at varying levels, while CD11b,
Figure 3 | β2 integrin involvement in immune cell function can be categorized into three processes: immune cell recruitment, immune cell interactions, and immune cell signaling. Dysregulation of these functions could contribute to conditions such as inflammation, immunity, and infection.

CD11c, and CD11d are predominantly expressed by monocytes, macrophages and DCs. Specifically, in humans, monocytes express all four β2 integrin-associated alpha subunits (CD11a, CD11b, CD11c, and CD11d) with CD11a and CD11b expression greater than CD11c (19, 20); macrophages express CD11a and CD11b at lower levels than monocytes together with CD11c at similar levels to monocytes (21); while DCs mainly express CD11c together with CD11a, though some DC subsets also express CD11b (22). While CD11d has received less attention than the other β2 integrins due to the absence of commercially available human antibodies, Miyazaki and colleagues showed CD11d expression on monocyte-derived DCs and macrophages as well as most circulating monocytes (23). To complement the scarce available data, mRNA expression data for the CD11d subunit ITGAD were consulted. While Villani and colleagues (24) find monocytes to express highest levels of ITGAD mRNA, the Expression Atlas (25) reports highest expression in DCs, with ITGAD expression in monocytes remaining below detectable threshold. However, overall both RNAseq data sets show that CD11d mRNA expression is very low in monocytes, macrophages, and DCs. 

Table 1
TABLE 1 | β2 integrin expression on dendritic cells (DCs), monocytes and macrophages—human and murine findings.

| Cell type | CD11a/CD18 (αL/β2) | CD11b/CD18 (αM/β2) | CD11c/CD18 (αx/β2) | CD11d/CD18 (αx/β2) |
|-----------|---------------------|---------------------|---------------------|---------------------|
| **DCs**  | Human: high levels of CD11a on monocyte-derived DCs (22, 27–29); plasmacytoid DCs (pDCs) also express CD11a (30); reduced CD11a/CD18 levels upon DC activation (51) | Human: CD11b present on monocyte-derived DCs (22, 27, 28); detected in cDCs, but not in pDCs (31–33); higher on cDC2 than cDC1s (33, 34); reduced CD11b/CD18 levels upon DC activation (51) | Human: pDCs lack CD11c (31); expressed on mature DCs (31); CD11c expression is higher on cDC2 than cDC1s (33, 34); monocyte-derived DCs also express CD11c (32); reduced CD11c/CD18 levels upon DC activation (31) | Human: expressed on monocyte-derived DCs (23); single-cell mRNA data suggests low gene expression in DCs (25) |
| **Mouse** | Mouse: expressed by cDCs, particularly the CD8+ subset, and by pDCs (35); also highly expressed by bone marrow-derived DCs | Mouse: expression of CD11b in mouse cDCs is subset-specific: higher on CD8+ than CD8- splenic DCs (35); expressed in sub-populations of gut DCs (38); absent from pDCs (37); expressed by bone marrow-derived DCs (38) | Mouse: CD11c highly expressed on cDCs and typically used as a DC marker (39); expressed by pDCs (39) and bone marrow-derived DCs (40) | Mouse: no protein expression data available, RNA-seq data suggest medium ITGAD gene expression in murine DCs (25) |
| **Monocytes** | Human: expressed by circulating monocytes (21, 29, 41) | Human: highly expressed by circulating monocytes (21, 34, 41); differentially expressed on osteoclast precursors (42) | Human: expressed on circulating monocytes (21, 34) and classical, non-classical, and intermediate monocytes (31) | Human: expressed on majority of circulating monocytes, higher on CD16+ cells compared to CD16− cells (23) |
| **Mouse** | Mouse: expressed by circulating monocytes (43) | Mouse: high expression of CD11b on murine monocytes (44) | Mouse: thought to be absent from most monocytes (45); though may be upregulated upon stimulation/maturation (44) | Mouse: lowly expressed by circulating monocytes, upregulated upon differentiation into macrophages (46), low ITGAD mRNA expression (25) |
| **Macrophages** | Human: expressed by monocyte-derived macrophages (21, 43); reduced expression on monocyte-derived macrophages compared to blood monocytes (21) | Human: expressed on monocyte-derived macrophages (47–49); expressed on alveolar macrophages, though at lower levels compared to blood monocytes (21) | Human: lowly expressed by monocyte-derived macrophages (21, 48–50) | Human: expressed on monocyte-derived macrophages in vitro (23) |
| **Mouse** | Mouse: expression dependent on tissue: present on pulmonary, but not on microglia, spleen or peritoneal macrophages (51) | Mouse: abundantly expressed by peritoneal macrophages (62, 53); highly expressed on dermal macrophages (54) | Mouse: expressed on alveolar macrophages (55); absent from bone marrow-derived macrophages and dermal macrophages (54) | Mouse: expressed by peritoneal macrophages (56) |

provides the details of expression of all β2 integrin subunits in human and murine monocytes, macrophages, and DCs. Where available, expression analysis on DC subsets is given using the Guilliams nomenclature (26), which was recently confirmed and expanded by Villani and colleagues (24).

Animal studies have been instrumental in elucidating integrin function in monocytes, macrophages, and DCs. β2 integrins are highly conserved across species, with mice, rats, and rabbits most commonly used as models. Importantly β2 integrin-deficient mice are considered an appropriate model of the human condition leukocyte adhesion deficiency (LAD) where β2 integrin expression or function is lost (57). However, while β2 integrin structure is largely similar between species, cellular expression levels can vary significantly. A common example is CD11c, which in mice is predominantly expressed by conventional (cDCs) and plasmacytoid DCs (pDCs), although can also be expressed on lymphocyte subsets. In humans, on the other hand, CD11c is expressed not only on DCs but also on monocytes, macrophages, granulocytes, and natural killer cells (19, 38). Animal and human studies therefore have to be compared with great care, and validation of concepts conceived in animal models in human cells remains a priority in elucidating the functions of β2 integrins.

### β2 Integrins as Regulators of Immune Function

#### Evidence for β2 Integrin Contribution to Immune Regulation

There is mounting evidence that puts β2 integrins at the center of the balance between immune priming and tolerance. Integrin-deficient humans and mouse models show that β2 integrins are important negative regulators of the immune system. LADs are genetic human disorders caused by the reduction or complete absence of β2-integrins (LAD-I) (58) or by mutations in the integrin-activating protein kindlin-3 (LAD-III) (59). These disorders are characterized by profound impairment of leukocyte recruitment to peripheral sites of infection. Patients with LAD suffer from increased susceptibility to infection and impaired inflammatory responses (60), resulting in markedly reduced lifespan if no therapeutic measures are taken. Paradoxically LAD patients also suffer from chronic inflammatory diseases. Examples of conditions prevalent in LAD patients include intestinal colitis (61) and periodontitis (62) suggest that β2 integrins have an important role in suppressing inflammation and promoting...
immune tolerance. Supporting this, the presence of functional β2 integrins improved symptoms in a model of skin inflammation by restricting DC-mediated T cell activation (63).

LAD pathology can be replicated in β2 integrin knockout (KO) mouse models, underlining the importance of β2 integrins for immune cell recruitment in both humans and murine models and the similarities between the species. From studies in KO mice and LAD patients, we know β2 integrins are essential in mediating T cell recruitment to lymph nodes and leukocyte, particularly neutrophil and T cell, recruitment to sites of inflammation. Here, we will further explore the roles of these integrins in monocytes, macrophages, and DCs.

**β2 Integrins Regulate Recruitment and Migration of Mononuclear Phagocytes**

Evidence suggests that leukocyte recruitment to tissues is dependent on β2 integrins, because of the requirement for these adhesion molecules in the firm adhesion to the endothelial layer under shear flow conditions and for subsequent transendothelial migration (64). However, leukocyte migration within tissues is thought to occur independently of β2 integrins, as cells use an actin-dependent flowing and squeezing mechanism of movement in three-dimensional environments (64).

Geissmann and colleagues showed that the adhesion of patrolling murine monocytes to blood vessel walls is significantly decreased when CD11a is blocked (45). Similarly, chemotactic migration of human monocytes *in vitro* is inhibited when CD18 function is blocked (65). However, murine monocyte recruitment to sites of inflammation was found to occur independently of CD11a and CD11b (66), suggesting that β2 integrins are primarily involved in the homeostatic migration of monocytes and that their role is redundant during inflammation. On the other hand, increased expression levels of CD11d on macrophages mediates their retention at inflammatory sites in mice (56).

The role of β2 integrins in DC and macrophage recruitment to secondary lymphoid organs and tissues seems to be dependent on the inflammatory state of the body. Bone marrow-derived DCs (BMDCs) from mice where all integrins, including β2, are knocked out, migrated from the site of injection (ear) to the draining lymph node in similar numbers to their wild-type counterparts when activated with lipopolysaccharide (LPS). This suggests that DC migration during inflammation is not dependent on integrins. However, under steady-state conditions, the absence of functional β2 integrins from murine BMDCs (using signaling-deficient β2 integrin knock-in BMDCs) was found to increase migration from tissue (footpad) to draining lymph node, leading to the hypothesis that β2 integrins function to restrict migration in the steady-state by anchoring DCs in the tissue site. As a consequence of increased DC migration to the draining lymph node, the same study showed an increase in Th1 cytokine production (67), further supporting a negative regulatory role for β2 integrins on DCs. In addition, a murine model of skin inflammation also showed an increase in migratory DCs in the draining lymph node of β2 integrin signaling-deficient mice, as well as at the site of inflammation, though whether this was dependent on the inflammation or not was not determined (63). Overall, the cellular environment seems to determine the requirement for functional β2 integrins in the migration of both monocytes and DCs *in vivo*: integrins play a role in monocyte recruitment and DC migration under steady-state conditions, but are dispensable during inflammation.

**β2 Integrins Regulating DC–T Cell Interactions**

In addition to their roles in leukocyte recruitment and migration, β2 integrins are also important mediators of cellular interactions. Functional β2 integrins are important in the formation of the immunological synapse between antigen-presenting cells (APCs) and T cells. The context and dynamics of this interaction determine whether T cells become activated or tolerized. β2 integrins, and their ligand, ICAM-1, are expressed by both the T cell and the APC and are vital in immune synapse formation. Importantly, it is becoming increasingly clear that β2 integrins expressed by the APC and T cell have opposing functions in the immune synapse, resulting in differential outcomes for the T cell response.

On the T cell side, CD11a clusters in the peripheral supramolecular activation cluster (P-SMAC) and binds to ICAM-1 on the APC (68). This molecular interaction stabilizes the connection made between T cell receptor and peptide:MHC on the APC in the central SMAC (16, 69), thereby enhancing TCR signal transduction (70). While T cell CD11a therefore has a largely pro-inflammatory effect, enhancing T cell activation, proliferation, and differentiation, a role for T cell integrins in regulation of activation, for example, in different T cell subsets, is not ruled out.

On the APC side of the immunological synapse, β2 integrins have also been shown to be involved, likely binding to ICAM-1 on the T cell. Importantly, the integrins on the APC regulate the outcome of the T cell response. For example, in murine models, active CD11b on DC surfaces inhibits the DC–T cell interaction (71). The reduced antigen-presenting capabilities of murine bone marrow-derived macrophages compared to BMDCs were therefore proposed to be due to their comparably larger surface expression of activated CD11b (71, 72). This suppressive role for DC CD11b has also been shown in human cells. When CD11b on human monocyte-derived DCs binds its ligand ICAM-1, both CD86 expression on DCs and DC-induced T cell proliferation were reduced (73). Interestingly, ligation of CD11b/CD18 decreases the ability of murine BMDCs to stimulate T cells and elicit a downstream response (74), CD11b/CD18 interactions can suppress Th1 cell differentiation (75), suggesting a strong role for this specific β2 integrin in immune regulation. This suggests that the activated conformation of CD11b/CD18 is extensively involved in regulating the immune system and has strong negative and positive regulatory functions depending on cell type they are expressed on.

Furthermore, the expression of activated β2 integrins on murine DC surfaces significantly reduces T cell activation (71) and further studies actually demonstrated an inverse relationship between forced activation of murine BMDC CD11a and T cell activation (72), suggesting a directly limiting effect of active β2 integrins on T cell activation by APCs.

Overall, the role of integrins as adhesion molecules carefully mediating and regulating cellular interactions is not to be underestimated for mounting an effective immune response.
**β2 Integrins Regulate Immune Cell Signaling**

In addition to their roles in leukocyte recruitment and interactions, several studies show that integrin outside-in signaling following ligand binding can directly affect cell function. Chinese Hamster Ovarian cells transfected with CD11c acquire the ability to bind both LPS and Gram-negative bacteria, as well as the ability to initiate downstream activation signals (76). In contrast to their anti-inflammatory roles on DCs, CD11b or CD11c receptor occupation on the surface of monocytes stimulates cell-specific pro-inflammatory pathways (77), such as secretion of IL-8, MIP1α, and MIP1β.

Generally, the interplay between TLR4- and β2 integrin-mediated signaling is controversial. On the one hand, it has been shown that CD11b positively regulates TLR4 signaling (78), especially in murine BMDCs. Several studies report β2 integrins act in synergy with LPS (79–81), therefore suggesting a potential pro-inflammatory role for CD11b. By contrast, other studies report that β2 integrins negatively affect TLR signaling. Complete absence of β2 integrins in mice (CD18 KO) was shown to result in a strong increase of TLR signaling (82) and the absence of CD11b specifically from murine macrophages causes exacerbated TLR-mediated inflammatory responses, resulting in increased susceptibility to endotoxin shock and Escherichia coli sepsis (83). Mechanistically, CD11b signaling has been shown to induce degradation of the key TLR signaling components, MyD88 and TRIF, directly dampening TLR responses in macrophages (83). Moreover, activation of CD11b on human inflammatory arthritis synovial macrophages via binding to its ligand ICAM was shown to indirectly inhibit TLR signaling (84) by inducing expression of IL-10 and the inhibitory factors SOCS3, ABIN-3, and A20. Integrins furthermore restrict TLR signaling on both murine macrophages and DCs (63). The role of β2 integrins in modulating TLR signaling is, therefore, complex, although one could tentatively propose that CD11b specifically seems to have opposing TLR4-mediated roles in inflammation, depending on the APC surface it is expressed on. However, while this could hold true for TLR4 signaling, this might not be the case for all TLRs. CD11b deficiency in murine BMDCs, while negatively affecting TLR4-mediated pathways, actually leads to an increase in DC cross-priming of cytotoxic T cells, a process mediated by the microRNA-146a (85). β2 integrin regulation of TLR-mediated responses therefore remains incompletely understood, with future studies hopefully elucidating the complex and intricate nature of these receptor interactions.

A variety of studies available suggest a significant immunoregulatory role for β2 integrins, not only by their mediation of adhesive and migratory processes, but also by immunological signaling. However, other studies suggest that, given the right cellular environment or cell type, β2 integrins can also have a strong pro-inflammatory effect (see Table 2 for comparison). When considering these opposing functions of integrins, it seems likely that even slight disturbances in integrin expression, signaling or activation could result in significant immunological effects, thus potentially contributing to a variety of autoimmune, inflammatory, and infectious conditions.

**β2 INTEGRINS IN INFLAMMATION, INFECTION, AND AUTOIMMUNITY**

Evidence for the role of β2 integrins in contributing to the development and progression of inflammatory and autoimmune conditions is accumulating. Considering that β2 integrin signaling can have opposing functions depending on subunit pairing and the immune cell type it is expressed on, it is not surprising that these receptors play important roles in both contributing to as well as negatively regulating inflammatory processes.

Human genetic studies point to a role of β2 integrins in inflammation and autoimmunity. A polymorphism of ITGAM, the CD11b subunit, increases the risk for the autoimmune disease systemic lupus erythematosus (87) (SLE), which shares genetic risk factors with rheumatoid arthritis (RA) (88). Disease risk for inflammatory bowel disease, similarly characterized by dysregulation of immune function specifically in the intestine, increases with amplified expression of alleles for both ITGAL, encoding CD11a, and the β2 integrin ligand ICAM1 (89). Gene expression of CD11d in humans and mice was found to be increased in white adipose tissue in obesity, a condition characterized by an increase in systemic inflammation (90). Furthermore, CD11d activation led to increased IL-1β expression (23), which when overproduced

---

**TABLE 2 | Summary of the roles for β2 integrins in monocytes, macrophages, and dendritic cells (DCs).**

| Cell type | Recruitment and migration | Interactions with T cells | Signaling |
|-----------|----------------------------|--------------------------|-----------|
| **Monocytes** | β2 integrins mediate recruitment of monocytes under homeostatic conditions (45, 65), but dispensable for recruitment during inflammation (66) | Yet to be determined | Yet to be determined |
| | | **Pro-inflammatory** | Unknown | Unknown |
| **Macrophages** | β2 integrins reported to mediate macrophage retention at inflammatory sites (64, 86) | Yet to be determined | β2 integrin signaling dampens macrophage responses to Toll-like receptor (TLR) stimulation (82, 83) |
| | | **Pro-inflammatory** | Unknown | **Regulatory** |
| **DCs** | Under homeostatic conditions β2 integrins restrict DC migration from tissue to lymph nodes (67); Migration from tissue site to draining lymph nodes during inflammation occurs independently of integrins (64) | DC integrins contribute to contact formation with T cells—this role inhibits full T cell activation (71, 72, 74) | β2 integrin signaling functions to restrict DC activation both in response to TLR stimulation and under homeostatic conditions (67) |
| | | **Regulatory** | **Regulatory** | **Regulatory** |
can contribute to a variety of autoinflammatory conditions (91). While dysregulation of \( \beta_2 \) integrin signaling seems likely to be involved in a variety of autoimmune diseases and inflammatory conditions, exact mechanisms are still unclear, and further investigation of both signaling pathways and genetic basis will be needed to fully elucidate their complex roles.

Recent studies have focused on \( \beta_2 \) integrin involvement in RA, which serves as an excellent example of the opposing roles \( \beta_2 \) integrins can take in disease. Expression of CD11a is increased in inflamed synovial tissue, where it is hypothesized to contribute to cell activation and on-going joint destruction (92, 93), but not in peripheral blood of RA patients. However, as CD11a is also involved in facilitating immune cell migration to sites of inflammation, clear-cut cause and effect of the presence of activated \( \beta_2 \) integrins in the synovium is difficult to establish. Blocking all \( \beta_2 \) integrins reduced inflammation in a rabbit RA model (94), while absence of CD11a led to complete resistance to disease induction in a KB x N serum transfer mouse model of arthritis (95). Furthermore, both a small molecule antagonist against CD11a and a CD11a-monoclonal antibody (mAb) proved to be similarly successful in reducing both inflammatory-mediated bone destruction and cytokine mRNA levels within the murine joint (96, 97). Mice with mutations in the \( \beta_2 \) integrin ligand ICAM-1 also show reduced susceptibility to the collagen-induced arthritis (CIA) model (98). Clearly, CD11a–ICAM-1 interactions are essential for leukocyte recruitment to the inflamed joint.

However, evidence is emerging that other \( \beta_2 \) integrins may function to control inflammation in arthritis. CD11b KO mice, for example, show exacerbated joint pathology in the KB x N serum transfer model of arthritis, underlining the starkly opposite roles different \( \beta_2 \) integrins can play (95). A recent study replicated these results in a CIA model and, furthermore, showed that exacerbated joint pathology resulted from elevated IL-6 levels and an increase in Th17 cell priming, which could be rescued by introducing a CD11b–expressing DC cell line (99). On the other hand, blocking CD11b immediately before onset of disease significantly reduced disease burden in two different models of arthritis (CIA and a DBA/1 to severe combined immunodeficiency transfer model of arthritis) (100), suggesting that the role of CD11b in inflammatory arthritis may differ depending on the cell type involved and the disease stage.

When considering the importance, as well as the obvious complexity, of \( \beta_2 \) integrin function in autoimmune diseases such as RA, therapeutically targeting \( \beta_2 \) integrins will have to be carefully balanced but also holds great promise to offer novel treatment options.

**APPLICABILITY OF INTEGRIN-TARGETING THERAPIES**

Modulating integrin function to improve mal-adaptation or excessive activation of the immune system is of great interest in a variety of autoimmune and inflammatory conditions. However, achieving efficacy without immunocompromising side effects might prove challenging. Here, we discuss the progress and failures in developing integrin-targeted therapies and speculate on the routes forward for success.

To date, targeting integrins therapeutically has had mixed success in the clinic. The only mAb targeting \( \beta_2 \) integrins, Efalizumab, which targets CD11a, was originally developed as a treatment for psoriasis (101). However, several patients presented with the potentially fatal disease progressive multifocal leukoencephalopathy (PML), caused by reactivation of the JC virus, which results in a white matter disorder of the brain (102). Although the mechanism of PML development in Efalizumab-treated patients was not investigated, we speculate that viral reactivation was likely either due to the loss of immune cell recruitment to the brain to control the virus (103) or due to the mAb itself crossing the blood–brain barrier (104). Due to the occurrence of PML, Efalizumab was withdrawn from European and American markets due to its associated safety issues in 2009.

Although targeting \( \beta_2 \) integrins has so far failed in the clinic, targeting other integrins for the treatment of colitis and Crohn’s disease has proved successful. The mAb against the \( \alpha_4 \beta_7 \) integrin, Natalizumab, was developed for the treatment of multiple sclerosis and Crohn’s disease (105, 106). This mAb binds to \( \alpha_4 \beta_7 \) and \( \alpha_5 \beta_1 \). However, PML also occurs in some Natalizumab-treated patients (integrin \( \alpha_4 \beta_7 \) is also involved in leukocyte recruitment to the brain) and so is no longer used widely (107). More recently, a specific \( \alpha_4 \beta_7 \) targeting mAb Vedolizumab has shown success in safety efficacy in Crohn’s disease and ulcerative colitis. This success story underlines the potential of targeting integrins for therapeutic purposes.

In order to realize the potential of targeting \( \beta_2 \) integrins therapeutically, it will be necessary to improve the strategy. As indicated by the success of Vedolizumab over Natalizumab, one way to do this is to target the right integrin subunit(s) in order to reduce the likelihood of side effects. Targeting CD11a, in the form of Efalizumab, proved unsuccessful in the clinic. As CD11a is expressed by almost all leukocytes, has vital roles in leukocyte recruitment and has immunoregulatory effects in mononuclear phagocytes, the resulting serious side effects from targeting this molecule therapeutically are, perhaps, not surprising. Targeting other CD11 subunits might be a more effective strategy. For example, CD11b, CD11c, and CD11d have a more restricted pattern of expression in leukocytes (predominantly on monocytes, macrophages, and DCs), which may make these molecules more suitable targets. Importantly, it is vital that we consider the pro- and anti-inflammatory functions of \( \beta_2 \) integrin subunits and design drugs to target them appropriately. CD11b, for example, has clear regulatory roles in macrophages and DCs, meaning that we could potentially exploit this immunosuppressive pathway by activating, rather than blocking, this integrin subunit. Such a strategy may have less risk of serious side effects. It is, therefore, essential that we fully understand the specific functions of individual integrin subunits in different leukocyte populations in order to target \( \beta_2 \) integrin subunits effectively in the clinic.

Another option to explore is blocking not the \( \beta_2 \) integrin itself, but the ligand of interest. Targeting the CD11a and CD11b ligand, ICAM-1, has shown beneficial results especially in early RA (108), although immunogenicity of the mAb in question restricts clinical use (109) and problems caused by impaired leukocyte recruitment prevail.
Further potential difficulties in developing integrin-targeting therapy include the close signaling relationships that exist in some integrins, potentially leading to complex downstream effects mediated even by an activating mAb highly specific for a β2 integrin (110). Carefully elucidating downstream signaling pathways and further increasing drug specificity is therefore essential to bring more integrin therapeutics into the clinic.

Innovative avenues to explore include computationally designed integrin proteins with constitutively activated or inactivated subunits, which could find applications in both pharmacological testing and therapy (111). Furthermore, developing small molecular drugs targeting β2 integrins viable for oral use remains a priority, as it could offer an alternative way to yield the same beneficial results without the dangerous side effects of mAbs. An example is the small molecule CD11b agonist, Leukadherin-1, which previous studies found to reduce monocyte-mediated TNF-release by mimicking natural ligand binding. When NK cells and monocytes were pre-treated with Leukadherin-1, innate inflammatory signaling in human ex vivo studies was suppressed (112). While the study noted some caveats, for example, the differences of CD11b function on different cell types (78), it is being explored for the treatment of SLE. Another small molecule currently in development is the CD11a antagonist BMS-587101, which acts by reducing CD11a-mediated adhesion and to a lesser extent T cell proliferation. It significantly improved both murine models of lung inflammation and transplant viability (113).

Continuous effort to increase drug specificity and further understand their complex delicate signaling networks will be needed to bring β2 integrin-targeting drugs into the clinic. But while the use of integrin-targeting drugs has been contentious in the past, their potential in treating a wide variety of immune diseases is enormous and should not be neglected.

CONCLUSION

This review explored the opposing nature of β2 integrin pro- and anti-inflammatory functions in three main immune functions, making them prime candidates to be both important mediators and regulators of the immune system. The first is migration, which allows for targeted immune cell recruitment to sites of infection and tissue damage. The second is adhesion, not only preceding immune cell extravasation at sites of inflammation, but also an important factor in initiating the adaptive immune response by facilitating cellular interactions. Finally, immune cell signaling, which allows for fine-tuned cooperation between a wide variety of immune cells. Considering the fact that β2 integrins play a complex role in three important areas of the immune system and their differential expression on monocytes, macrophages and DCs, it becomes clear that the variety of studies presented in this review is by no means exhaustive. The common message is evident: β2 integrins are involved in complex immunoregulatory signaling pathways. However, in addition to their well-established pro-inflammatory roles in recruitment and activation, β2 integrins also have essential immunoregulatory functions. Dysregulated integrin signaling, expression and surface activation is therefore likely to contribute to a variety of inflammatory and autoimmune conditions. Elucidating the function of β2 integrins further therefore promises to provide novel therapeutic targets for various disorders, RA being just one example.

AUTHOR CONTRIBUTIONS

CH and VM designed the structure of the review. LS wrote the first draft. CH and VM revised the manuscript. LS composed the figures. All authors have seen and agreed on the finally submitted version of the manuscript.

ACKNOWLEDGMENTS

The authors are supported by Arthritis Research UK (grant number 20848 to VM) and the Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE) (grant number 20298). They thank Dr. Megan MacLeod for critically reading the manuscript.

REFERENCES

1. Mould AP, Humphries MJ. Regulation of integrin function through conformational complexity: not simply a knee-jerk reaction? Curr Opin Cell Biol (2004) 16(5):544–51. doi:10.1016/j.ceb.2004.07.003
2. Adair BD, Xiong JP, Maddock C, Goodman SL, Arnaout MA, Yeager M. Three-dimensional EM structure of the ectodomain of integrin αβ3 in a complex with fibronectin. J Cell Biol (2005) 168(7):1109–18. doi:10.1083/jcb.200410068
3. Byron A, Humphries JD, Askari JA, Craig SE, Mould AP, Humphries MJ. Anti-integrin monoclonal antibodies. J Cell Sci (2009) 122(22):4009–11. doi:10.1242/jcs.058770
4. Stewart M, Hogg N. Regulation of leukocyte integrin function: affinity vs. avidity. J Cell Biochem (1996) 61(4):554–61. doi:10.1002/jcb.2686141055
5. Hogg N, Patzak I, Willenbrock F. The insider’s guide to leukocyte integrin signalling and function. Nat Rev Immunol (2011) 6:416–26. doi:10.1038/nri2986
6. Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci (2009) 122(2):159–63. doi:10.1242/jcs.018093
7. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, et al. Talin binding to integrin α tails: a final common step in integrin activation. Science (2003) 302(5642):103–6. doi:10.1126/science.1086652
8. Moser M, Niewandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med (2008) 14(3):325–30. doi:10.1038/nm1722
9. Moser M, Bauer M, Schmid S, Ruppert R, Schmidt S, Sixt M, et al. Kindlin-3 is required for β2 integrin-mediated leukocyte adhesion to endothelial cells. Nat Med (2009) 15(3):300–5. doi:10.1038/nm1921
10. Constantin G, Majeed M, Giagulli C, Piccio L, Kim JY, Butcher EC, et al. Chemokines trigger immediate β2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity (2000) 13(6):759–69. doi:10.1016/s1074-7613(00)00074-1
11. Chung KJ, Mitroulis I, Wiessner JR, Zheng YY, Siegert G, Sperandio M, et al. A novel pathway of rapid TLR-triggered activation of integrin-dependent leukocyte adhesion that requires Rap1 GTPase. Mol Biol Cell (2014) 25(19):2948–55. doi:10.1091/mbc.E14-04-0867
12. Bazzoni G, Hemler ME. Are changes in integrin affinity and conformation overemphasized? Trends Biochem Sci (1998) 23(1):30–4. doi:10.1016/s0968-0004(97)01141-9
13. Carman CV, Springer TA. Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr Opin Cell Biol (2003) 15(3):347–56. doi:10.1016/j.ceb.2003.08.003
14. Iwamoto DV, Calderwood DA. Regulation of integrin-mediated adhesions. Curr Opin Cell Biol (2015) 36:41–7. doi:10.1016/j.ceb.2015.06.009
15. von Andrian UH, Chambers JD, McEvoy LM, Bargatze RF, Arfors KE, Iwamoto DV, Calderwood DA. Regulation of integrin-mediated adhesions in vivo. Proc Natl Acad Sci U S A (1991) 88(17):7538–42. doi:10.1073/pnas.88.17.7538
16. Podolakova NP, Podolakov AV, Haas TA, Lishko VK, Ugarova TP. Ligand recognition specificity of integrin leucine zipper (Mac-1, CD11b/CD18) and its functional consequences. Biochemistry (2015) 54(6):1408–20. doi:10.1021/bi5013782
17. Miyazaki Y, Vieira-de-Abreu A, Harris ES, Shah AM, Weyrich AS, Castro-Diez MC, et al. CD11c/CD18 dominates adhesion of human monocytes, macrophages and dendritic cells: what’s the difference? Trends Immunol (2014) 35(6):270–7. doi:10.1016/j.it.2014.04.003
18. Yakubenko VP, Yadav SP, Ugarova TP. Integrin αδβ2, an adhesion receptor up-regulated on macrophage foam cells, exhibits multiligand-binding properties. Blood (2006) 107(4):1643–50. doi:10.1182/blood-2005-05-2659
19. Sándor N, Lukács S, Ungai-Salánski O, Orgován N, Szabó B, Horváth R, et al. CD11c/CD18 dominates adhesion of human monocytes, macrophages and dendritic cells over CD11b/CD18. PLoS One (2016) 11(9):e0163120. doi:10.1371/journal.pone.0163120
20. Erdei A, Lukács S, Mácsik-Valent B, Nagy-Baló Z, Kurucz I, Bajtay Z. Non-identical twins: different faces of CR3 and CR4 in myeloid and lymphoid cells of mice and men. Semin Cell Dev Biol (2017). doi:10.1016/j.semcdb.2017.11.025
21. Prieto J, Eklund A, Patarroyo M. Regulated expression of integrins and other adhesion molecules during differentiation of monocytes into macrophages. Cell Immunol (1994) 156(1):191–211. doi:10.1006/cimm.1994.1164
22. Freundenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci U S A (1990) 87(19):7698–702. doi:10.1073/pnas.87.19.7698
23. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. The distinct surface of human blood dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor. J Exp Med (2015) 36:41–7. doi:10.1084/jem.2015.06.009
24. Ferretti PS, Steinman RM. The distinct surface of human blood dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor. J Exp Med (2015) 36:41–7. doi:10.1084/jem.2015.06.009
25. Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science (2017) 356(6355):eaab4573. doi:10.1126/science.aab4573
26. EMBL-EBI Expression Atlas Development Team, github.com/gxa/atlas/graphical-contributors. Expression atlas. EMBL-EBI Gene Expression Atlas. European Molecular Biology Laboratory - European Bioinformatics Institute (2017). Available from: http://www.ebi.ac.uk/gxa/home
27. Guillaums M, Ginhoux F, Jakubzick C, Naik SH, Orai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogenic. Nat Rev Immunol (2014) 14(8):571–8. doi:10.1038/nri3712
28. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells, monocytes, and progenitors. Science (1998) 280(5365):eaab4573. doi:10.1126/science.aab4573
29. Lo Celso E, Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells, monocytes, and progenitors. Science (1998) 280(5365):eaab4573. doi:10.1126/science.aab4573
30. Guilliams M, Ginhoux F, Naik SH, Onai N, Schraml BU, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science (2017) 356(6355):eaab4573. doi:10.1126/science.aab4573
31. Geijtenbeek TB, Toressma T, van Vliet SJ, van Duijnhoven GC, Aedema GJ, van Kooyk Y, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell (2000) 100(5):575–85. doi:10.1016/S0092-8674(00)00869-5
32. Ammon C, Meyer SP, Schwarzfischer L, Krause SW, Andresen R, Kreutz M. Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells. Immunology (2000) 100(3):364–9. doi:10.1046/j.1365-2567.2000.00506.x
33. de la Rosa G, Longo N, Rodríguez-Fernández JL, Puig-Kroger A, Pineda A, Corbi AL, et al. Migration of human blood dendritic cells across endothelial cell monolayers: adhesion molecules and chemokines involved in a subset-specific transmigration. J Leukoc Biol (2003) 73(5):639–49. doi:10.1189/jlb.1b.0503
34. Rieckmann JC, Geiger R, Hornburg D, Wolf T, Kveler K, Jarrossay D, et al. Social network architecture of human immune cells unveiled by quantitative proteomics. Nat Immunol (2017) 18(5):583–93. doi:10.1038/nl.3693
35. Schlesinger LS, Horwitz MA. Phagocytosis of Escherichia coli by human monocyte-derived macrophages is mediated by complement receptors CR1 (CD35), CR3 (CD11b/CD18), and CR4 (CD11c/CD18) and IFN-gamma activation inhibits complement receptor function and phagocytosis of this bacterium. J Immunol (1991) 147(6):1983–94.
36. Perrone LA, Plowden JK, Garcia-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog (2008) 4(8):e1000115. doi:10.1371/journal.ppat.1000115
37. Reinauer H, Kayal S, Join-Lambert O, Fogg D, Auffray C, Elain G, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie...
the identity and diversity of mouse tissue macrophages. Nat Immunol (2012) 13(11):1118–28. doi:10.1038/ni.2419
52. Beller DI, Springer TA, Schuler RD. Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med (1982) 156(4):1000–9. doi:10.1083/jem.156.4.1000
53. Drevets DA, Leenen PJ, Campbell PA. Complement receptor type 3 (CD11c/CD18) involvement is essential for killing of Listeria monocytogenes by mouse macrophages. J Immunol (1993) 151(10):5431–9.
54. Tamoutounour S, Guilliams M, Montanana Sanchis F, Liu H, Terhorst D, et al. CD11c+ conventional and monocyte-derived dendritic cells in mouse skin. Immunity (2013) 39(3):925–38. doi:10.1016/j.immuni.2013.10.004
55. Vermaelen K, Pauwels R. Accurate and simple discrimination of mouse pulmonary dendritic cell and macrophage populations by flow cytometry: methodology and new insights. Cytometry A (2004) 61(2):170–7. doi:10.1002/cyto.a.20064
56. Yangken VP, Belevych N, Mishchuk D, Schurin A, Lam SC, Ugavora TP. The role of integrin αβ2 (CD11a/CD18) in monocyte/macrophage migration. Exp Cell Res (2008) 314(14):2569–78. doi:10.1016/j.yexcr.2008.05.016
57. Scharffetter-Kochanek K, Lu H, Norman K, van Nood N, Munoz F, Grabbe S, et al. Spontaneous skin ulceration and defective T cell function in CD18 null mice. J Exp Med (1998) 188(1):119–31. doi:10.1083/jem.188.1.119
58. Harris ES, Weyrich AS, Zimmerman GA. Lessons from rare maladies: leukocyte adhesion deficiency syndrome. Curr Opin Hematol (2010) 17(2):101–8. doi:10.1097/MOH.0b013e32833a0911
59. Robert P, Canault M, Farnarier C, Nurden A, Grosdidier C, Barlogis V, et al. Heterogeneous mutations in the αβ2 integrin subunits cause congenital leukocyte adhesion deficiency-deficiency-associated periodontitis. Blood (2007) 110(10):3546–54. doi:10.1182/blood-2006-02-1735
60. Vermaelen K, Pauwels R. Accurate and simple discrimination of mouse pulmonary dendritic cell and macrophage populations by flow cytometry: methodology and new insights. Cytometry A (2004) 61(2):170–7. doi:10.1002/cyto.a.20064
61. D'agata ID, Paradis K, Chad Z, Bonny Y, Seidman E. Leucocyte adhesion deficiency deficiency. Blood (2010) 115(7):1343–50. doi:10.1182/blood-2009-05-224428
62. Podgornska S, Kamaloo M, Ouyang H, Shi M, Zheng L, Stockwell TD, et al. Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism. J Immunol (2009) 183(3):1767–79. doi:10.4049/jimmunol.0802167
63. Behrens EM, Siriram U, Shivvers DK, Gallucci M, Ma Z, Finkel TH, et al. Complement receptor 3 ligation of dendritic cells suppresses their stimulatory capacity. J Immunol (2007) 178(10):6268–79. doi:10.4049/jimmunol.178.10.6268
64. Ehrichou D, Xiong Y, Xu G, Chen W, Shi Y, Zhang L. CD11b facilitates the development of peripheral tolerance by suppressing Th1 differentiation. J Exp Med (2007) 204(7):1519–24. doi:10.1084/jem.20062292
65. Listgall RR, Golenbock DT. CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med (1995) 181(4):1473–9. doi:10.1084/jem.181.4.1473
66. Rezzonico R, Imbert V, Chicheportiche R, Dayer JM. Ligation of CD11b and CD11c p integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1α (MIP-1α) and MIP-1β production in primary human monocytes through a pathway dependent on nuclear factor-κB. Blood (2001) 97(10):2932–40. doi:10.1182/blood.V97.10.2932
67. Ling GS, Bennett J, Woolard KJ, Szajna M, Fossati-Jimack L, Taylor PR, et al. Integrin CD11b positively regulates TRAIL-induced signalling pathways in dendritic cells but not in macrophages. Nat Commun (2014) 5:3039. doi:10.1038/ncomms4039
68. Fan ST, Edgington TS. Coupling of the adhesive receptor CD11b/CD18 to a mature migratory phenotype. Blood (1991) 87(1):50. doi:10.1182/bloodjci115000
69. Ingalls RR, Arnaout MA, Golenbock DT. Outside-in signaling by lipopolysaccharide through a tailless integrin. J Immunol (1997) 159(1):433–8.
70. Perera PY, Mayadas TN, Takeuchi O, Akira S, Zaks-Zilberman M, Goyert SM, et al. CD11b/CD18 acts in concert with CD14 and toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol (2001) 166(1):574–81. doi:10.4049/jimmunol.166.1.574
71. Yee NK, Hamerjan MA. β2 integrins inhibit TLR responses by regulating NF-κB pathway and p38 MAPK activation. Eur J Immunol (2013) 43(3):779–92. doi:10.1002/eji.201242550
72. Han C, Jin J, Xu S, Liu H, Li N, Cao X. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol (2010) 11(8):734–42. doi:10.1038/ni.1908
73. Wang L, Gordon RA, Huynh L, Su X, Park Min KH, Han J, et al. Indirect inhibition of toll-like receptor and type I interferon responses by ITAM-coupled receptor for lipopolysaccharide. Immunity (2010) 32(4):518–30. doi:10.1016/j.immuni.2010.03.014
74. Bai Y, Qian C, Qian L, Ma F, Hou J, Chen Y, et al. Integrin CD11b negatively regulates TLR9-triggered dendritic cell cross-priming by upregulating microRNA-146a. J Immunol (2012) 188(11):5293–302. doi:10.4049/jimmunol.1102371
75. Kushchayeva Y, Mishchuk D, Ugavora T. The role of beta 2 integrins in macrophage migration during resolution of inflammation. Blood (2009) 114:3600.
76. Nath SK, Han S, Kim-Howard X, Kelly JA, Viswanathan P, Gilkeson GS, et al. A nonsynonymous functional variant in integrin-aM (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet (2008) 40(2):152–4. doi:10.1038/ng.71
77. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med (2007) 357(10):977–86. doi:10.1056/NEJMoa073003
78. de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet (2017) 49(2):236–61. doi:10.1038/ng.7766
79. Thomas AP, Dunn TN, Oort PJ, Grino M, Adams SH. Inflammatory phenotype identifies CD14+ as a gene markedly induced in white adipose tissue in obese rodents and women. J Nutr (2011) 141(6):1172–80. doi:10.3945/jn.111.127068
91. Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med (2011) 269(1):16–28. doi:10.1111/j.1365-2796.2010.02313.x

92. Cuss JJ, Lipsky PE. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum (1988) 31(10):1230–8. doi:10.1002/art.1780311003

93. Takahashi H, Söderström K, Nilsson E, Kieseier BC, Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Natalizumab for active Crohn’s disease. N Engl J Med (2003) 348(1):24–32. doi:10.1056/NEJMoa020732

94. Jasin HE, Lightfoot E, Davis LS, Rothlein R, Faanes RB, Lipsky PE. Blocking interleukin-1β affinity conformation. Blood (1996) 87(12):4335–38. doi:10.1182/blood-1996-06-77978

95. Grönholm M, Jahan F, Bryushkova EA, Madhavan S, Aglialoro F, Soto Hinojosa L, et al. LFA-1 (αLβ2) small-molecule antagonist reduces inflammation and joint destruction in murine models of arthritis. J Immunol (2010) 184(7):3917–26. doi:10.4049/jimmunol.0901095

96. Grünwestein M, Schmid RH, Simic M, Drachenberg C, Wenzel C, Wusthoff C, et al. Natalizumab for active Crohn’s disease. N Engl J Med (2003) 348(1):24–32. doi:10.1056/NEJMoa020732

97. Berger JR, Fox RJ. Reassessing the risk of natalizumab-associated PML. J Neurovirol (2016) 22(4):333–3. doi:10.1007/s13365-016-0427-6

98. Shimaoka M, Shifman JM, Jing H, Takagi J, Mayo SL, Springer TA. Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. J Immunol (1996) 157(7):3153–8.

99. Stevanin M, Busso N, Chobaz V, Pigni M, Ghassem-Zadeh S, Zhang L, et al. CD11b regulates the Treg/Th17 balance in murine arthritis via IL-6. Eur J Immunol (2017) 47(4):637–45. doi:10.1002/eji.201646565

100. Taylor PC, Chu CQ, Plater-Zyberk C, Maini RN. Transfer of type II collagen-induced arthritis from DBA/1 to severe combined immunodeficiency mice can be prevented by blockade of Mac-1. J Immunol (1996) 88(2):315–21. doi:10.4049/jimmunol.1365-2567.1996.tb00021.x

101. Leonard CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 52(3):425–33. doi:10.1016/j.jaad.2004.09.029

102. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Arnu Rev Med (2010) 61:55–47. doi:10.1146/annurev.med.080708.082655

103. Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, et al. Fatal PML associated with efalizumab therapy insights into integrin αLβ2 in JC virus control. Neurology (2012) 78(7):458–67. doi:10.1212/WNL.0b013e3182478d4b

104. Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M; Progressive Multifocal Leukoencephalopathy Consortium. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord (2015) 8(6):255–73. doi:10.1177/1756285615602832

105. Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 354(9):899–910. doi:10.1056/NEJMoa044397

106. Shimaoka M, Shifman JM, Jing H, Takagi J, Mayo SL, Springer TA. Computational design of an integrin I domain stabilized in the open high affinity conformation. Nat Struct Mol Biol (2000) 7(8):674–8. doi:10.1038/12803

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling Editor declared a shared affiliation, though no other collaboration, with the authors LS and CH.

Copyright © 2017 Schittenhelm, Hilken and Morrison. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.